Maharashtra FDA strikes again, brings the axe down on Cipla's drug sale licences over irregularities
Cipla Pharma & Life Sciences’ Pune C&F unit has lost its drug sale licences following multiple violations found by the Maharashtra FDA. The regulator flagged misbranding of Reactin Plus Tablets, incomplete recall compliance, stock mismatches, improper storage and poor handling of expired medicines.